Exhibit 1
Top Alliances In April 2013
Welcome to In Vivo
Create an account to read this article
Already a subscriber?
Deals In Depth: April 2013
Roche is optioning Isis’ Huntington’s disease antisense candidates in a deal worth $282 million and Thermo Fisher paid just over $15 billion for Life Technologies. Biopharma financing was up 23% to $1.2 billion, device fundraising down 35% to $338 million.
More from Deal-Making
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
• By
An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
• By
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
More from In Vivo
• By
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
• By
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.